A Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of NTP42:KVA4 in Healthy Volunteers
Latest Information Update: 13 Jul 2023
Price :
$35 *
At a glance
- Drugs NTP 42 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors ATXA Therapeutics
- 24 May 2023 Results presented at the 119th International Conference of the American Thoracic Society
- 23 Feb 2022 Status changed from recruiting to completed.
- 14 Jun 2021 New trial record